The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naïve CLL/SLL (PCYC-1130): iLLUMINATE.
 
Ian Flinn
Research Funding - Janssen; Pharmacyclics
 
Carol Moreno
No Relationships to Disclose
 
Devinder Singh Gill
Honoraria - Roche Pharma AG
Consulting or Advisory Role - Janssen-Cilag
Speakers' Bureau - Roche Pharma AG
 
Thomas J. Kipps
Research Funding - Pharmacyclics
 
Yun Shaw
Employment - Pharmacyclics
Stock and Other Ownership Interests - Pharmacyclics
Travel, Accommodations, Expenses - Pharmacyclics
 
Yunfeng Li
Employment - Pharmacyclics
Stock and Other Ownership Interests - Pharmacyclics
 
Lori Appel Styles
Employment - PharmaMar
 
Danelle Frances James
Employment - Pharmacyclics
 
John G. Gribben
Honoraria - Celgene; Gilead Sciences; Janssen; Pharmacyclics; Roche Pharma AG
Consulting or Advisory Role - Celgene
Travel, Accommodations, Expenses - Gilead Sciences; Roche Pharma AG